Masimo (MASI) Getting Somewhat Favorable Media Coverage, Analysis Shows

Media stories about Masimo (NASDAQ:MASI) have trended somewhat positive on Thursday, Accern reports. The research firm identifies negative and positive press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Masimo earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 45.9317119028175 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

These are some of the news stories that may have impacted Accern Sentiment’s analysis:

Masimo (NASDAQ MASI) traded down $1.59 on Thursday, reaching $85.52. The company had a trading volume of 373,924 shares, compared to its average volume of 610,217. Masimo has a 12-month low of $62.96 and a 12-month high of $104.71. The firm has a market cap of $4,552.74, a PE ratio of 33.76, a P/E/G ratio of 2.97 and a beta of 0.72.

Masimo (NASDAQ:MASI) last issued its quarterly earnings results on Tuesday, October 31st. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.53 by $0.17. Masimo had a return on equity of 22.17% and a net margin of 45.83%. The company had revenue of $193.69 million for the quarter, compared to analysts’ expectations of $189.01 million. During the same period last year, the firm earned $0.52 EPS. The firm’s revenue for the quarter was up 15.6% on a year-over-year basis. equities research analysts predict that Masimo will post 2.95 EPS for the current fiscal year.

Several analysts recently issued reports on MASI shares. Zacks Investment Research raised Masimo from a “hold” rating to a “buy” rating and set a $98.00 price target on the stock in a report on Thursday, November 2nd. Stifel Nicolaus reissued a “buy” rating and issued a $108.00 price target on shares of Masimo in a report on Friday, November 3rd. BTIG Research raised Masimo from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Monday, August 14th. Finally, BidaskClub cut Masimo from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $97.17.

In other news, Director Steven Barker sold 10,000 shares of Masimo stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $90.00, for a total transaction of $900,000.00. Following the transaction, the director now directly owns 73,249 shares in the company, valued at approximately $6,592,410. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Yongsam Lee sold 13,976 shares of Masimo stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $89.43, for a total value of $1,249,873.68. Following the transaction, the executive vice president now owns 74,000 shares in the company, valued at $6,617,820. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,074 shares of company stock worth $4,737,245. 16.60% of the stock is owned by insiders.

WARNING: This piece was first published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at

Masimo Company Profile

Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.

Insider Buying and Selling by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Co. and related companies with's FREE daily email newsletter.

Leave a Reply